Showing results (241-250 of 760) with videos related to
Sort By:
Pageof 76
Future Oncology (London, England)|December 23, 2017
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study designPaul G Richardson, Michel Attal, Frank Campana, et al.Blood|July 23, 2025
A BCMA-mRNA vaccine is a promising therapeutic for multiple myelomaDebasmita Dutta, Jiye Liu, Kenneth Wen, et al.British Journal of Haematology|December 1, 2010
PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivoAjita V Singh, Madhavi Bandi, Monette A Aujay, et al.Expert Review of Proteomics|November 15, 2018
The power of proteasome inhibition in multiple myelomaThomas A Guerrero-Garcia, Sara Gandolfi, Jacob P Laubach, et al.Future Oncology (London, England)|April 3, 2015
The investigational proteasome inhibitor ixazomib for the treatment of multiple myelomaPaul G Richardson, Philippe Moreau, Jacob P Laubach, et al.Current Hematologic Malignancy Reports|October 16, 2012
New proteasome inhibitors in myelomaPanisinee Lawasut, Dharminder Chauhan, Jacob Laubach, et al.Experimental Hematology|March 8, 2002
Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: functional implicationsYu-Tzu Tai, Klaus Podar, Stine-Kathrein Kraeft, et al.British Journal of Haematology|May 20, 2003
Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cellsToshiaki Hayashi, Steven P Treon, Teru Hideshima, et al.Cancer Research|April 17, 2002
S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in miceSuzanne Lentzsch, Michael S Rogers, Richard LeBlanc, et al.British Journal of Haematology|September 15, 2007
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myelomaIris Breitkreutz, Marc S Raab, Sonia Vallet, et al.Pageof 76